Chapter 36 Treatment of gout and hyperuricemia

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


There are two aspects to the management of gout: treatment of episodes of acute gouty arthritis and sustained correction of hyperuricemia. Acute gout is most commonly treated with non-steroidal anti-inflammatory drugs or oral colchicine. Other modalities, including intravenous colchicine, intra-articular corticosteroid injection, ACTH, and systemic corticosteroids may be used in special circumstances. Correction of hyperuricemia is the only definitive means to reduce the incidence of acute gout and to prevent the development of tophaceous gout, a chronic, potentially debilitating form of gouty arthritis. Urate-lowering drugs are indicated when the patient has recurrent episodes of acute gouty arthritis, tophaceous deposits, or nephrolithiasis. Two types of urate-lowering drugs are available, uricosuric agents which increase the renal excretion of uric acid and a xanthine oxidase inhibitor, allopurinol, which blocks the formation of uric acid. Allopurinol is the preferred drug in patients with tophaceous gout, nephrolithiasis, significant renal impairment, and overproduction of uric acid.

Original languageEnglish (US)
Pages (from-to)723-735
Number of pages13
JournalPrinciples of Medical Biology
Issue numberC
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Chapter 36 Treatment of gout and hyperuricemia'. Together they form a unique fingerprint.

Cite this